Table 1 Baseline characteristics of study population based on the absence or presence of NOAF

Male, n(%)

44(83%)

519(84.1%)

0.834

Age,(y)

70.6 ± 12.82

60.54 ± 13.17

<0.001

Height(cm)

166.49 ± 7.13

167.78 ± 6.9

0.190

Weight(kg)

64.31 ± 9.32

70.49 ± 11.34

<0.001

BMI(kg/m2)

23.14 ± 2.55

24.96 ± 3.20

<0.001

Heart rate at admission(bpm)

80(70.5–95)

78(70–89)

0.155

SBP(mmHg)

131.37 ± 28.97

138.47 ± 26.07

0.059

DBP(mmHg)

76.19 ± 15.56

83.15 ± 17.17

0.004

Current smoker, n(%)

21(39.6%)

299(48.5%)

0.217

Current drinker, n(%)

16(30.2%)

189(30.6%)

0.946

Medications

ACEI/ARB, n(%)

12(22.6%)

136(22%)

0.920

Beta-blocker, n(%)

5(9.4%)

48(7.8%)

0.669

Calcium-blocker, n(%)

24(45.3%)

210(34%)

0.100

Statin, n(%)

5(9.4%)

60(9.7%)

0.945

Aspirin, n(%)

6(11.3%)

63(10.2%)

0.802

Clopidogrel, n(%)

4(7.5%)

37(6%)

0.652

Comorbidities

Hypertension, n(%)

37(69.8%)

354(57.5%)

0.080

Diabetes, n(%)

19(35.8%)

137(22.2%)

0.024

History of stroke, n(%)

7(13.2%)

36(5.8%)

0.036

History of coronary heart disease, n(%)

4(7.5%)

37(6%)

0.946

Laboratory tests

WBC (10⁹/L)

9.83(8.39–12.90)

8.67(6.72–11.16)

0.001

Lym (10⁹/L)

1.40(1.03–2.07)

1.70(1.24–2.28)

0.061

Mon (10⁹/L)

0.50(0.40–0.69)

0.45(0.33–0.60)

0.166

Neu (10⁹/L)

7.6(5.50–10.50)

5.85(4.28–8.40)

<0.001

RBC (10⁹/L)

4.56(4.02–4.75)

4.64(4.25–5.02)

0.042

Plt (10⁹/L)

181(139.50–210)

207(175–248)

<0.001

Hs-CRP(mg/L)

7.70(2.00-56.55)

2.80(1.30–7.25)

<0.001

Serum fibrinogen(g/L)

4.27(3.025–5.685)

3.010(2.530–3.750)

<0.001

Serum albumin(g/dL)

3.47(3.28–3.71)

3.74(3.55–3.95)

<0.001

FAR(10^− 3)

1.226(0.826–1.558) 0.796(0.659–1.005)

<0.001

TC (mmol/L)

4.30(3.57–5.11)

4.58(3.96–5.36)

0.041

TG (mmol/L)

1.06(0.77–1.61)

1.49(1.08–2.15)

<0.001

HDL-C (mmol/L)

0.95(0.80–1.07)

0.93(0.81–1.07)

0.797

LDL-C (mmol/L)

2.64(2-3.27)

2.86(2.27–3.47)

0.040

Lipoprotein(a) (mg/L)

175(108-377.5)

180.5(91.25–330)

0.716

Uric-acid (umol/L)

362(316.50–460)

358(288.5–434)

0.163

Scr (umol/L)

93.7(81.25–107)

80.8(71.8-92.25)

<0.001

eGFR (mL/min*1.73m²)

72.75 ± 27.26

89.84 ± 22.19

<0.001

BNP (pg/mL)

400.2(155.8-1075.05)119.10(46.70-266.60)

<0.001

cTnI (ug/L)

4.35(0.48–16.21)

0.99(0.16–5.82)

0.004

Echocardiography results

LA (mm)

40.68 ± 4.51

37.19 ± 4.54

<0.001

LVEF (%)

50(41.5–58)

60(53–65)

<0.001

Type of AMI, n (%)

STEMI

32(60.4%)

292(47.3%)

0.068

NSTEMI

21(39.6%)

325(52.7%)

0.068

Coronary artery stenosis>50%, n (%)

LM

1(1.9%)

44(7.1%)

0.144

LAD

46(86.8%)

548(88.8%)

0.656

LCX

45(84.9%)

379(61.4%)

0.001

RCA

three-vessel disease

44(83%)

35(66.0%)

422(68.4%)

279(45.2%)

0.027

0.004

Killip class, n (%)

I

16(30.8%)

481(78%)

<0.001

II

23(44.2%)

87(14.1%)

<0.001

III

8(15.1%)

21(3.4%)

<0.001

IV

8(15.1%)

28(4.5%)

0.001